Nicole Lamanna

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson et al. · Haematologica · 2018 · 439 citations · Full text

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 414 citations · Full text

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 372 citations · Full text

Hematological Malignancy, Interim Analysis, Lymphoid Neoplasia +9